dr. A. Diepstra

pathologist and post-doc researcher

Research

  1. 2019
  2. 2018
  3. Schrader, A. M. R., Jansen, P. M., Willemze, R., Vermeer, M. H., Cleton-Jansen, A-M., Somers, S. F., ... Vermaat, J. S. P. (2018). High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood, 131(18), 2086-2089. https://doi.org/10.1182/blood-2017-12-822817
  4. Viganò, E., Gunawardana, J., Mottok, A., Van Tol, T., Mak, K., Chan, F. C., ... Steidl, C. (2018). Somatic IL4R Mutations in Primary Mediastinal Large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. Blood, 131(18), 2036-2046. https://doi.org/10.1182/blood-2017-09-808907
  5. Nijland, M., Boslooper, K., van Imhoff, G., Kibbelaar, R., Joosten, P., Storm, H., ... Hoogendoorn, M. (2018). Relapse in stage I(E) diffuse large B-cell lymphoma. HEMATOLOGICAL ONCOLOGY, 36(2), 416-421. https://doi.org/10.1002/hon.2487
  6. 2017
  7. Somers, S., Jansen, P., Veelken, H., Vermeer, M., Kraan, W., Schrader, A-R., ... Vermaat, J. (2017). High Prevalence of Oncogenic MYD88 and CD79B Mutations in Intravascular Large B-Cell Lymphoma: Implication for Therapy with Bruton's Kinase Inhibitors? Blood, 130.
  8. 2016
  9. Abdul Razak, F. R., Diepstra, A., Jong, D., Koerts, J., Rutgers, B., Kluiver, J., ... Berg, van den, A. (2016). Mutations in CD58 and MYB in Hodgkin Lymphoma. Haematologica, 101, 4-5. [P031].
  10. Pegtel, D. M., Drees, E., van Eijndhoven, M. A. J., Groenewegen, N. J., van Niele, S., Prins, R., ... de Jong, D. (2016). Plasma vesicle-associated mirnas as therapy response biomarkers in hodgkin lymphom. Haematologica, 101, 31. [T013].
Previous 1 2 3 Next

ID: 197725